Oncology

Rodney Pommier, MD, FACS, professor of surgery, division of surgical oncology, school of medicine, Oregon Health & Science University, addresses the questions surrounding the efficacy of perioperative octreotide treatment for patients experiencing a carcinoid crisis.

Rodney Pommier, MD, FACS, professor of surgery, division of surgical oncology, school of medicine, Oregon Health & Science University, discusses what octreotide is and how it is used to reduce carcinoid crisis rates or treat a crisis.

NETs can occur almost anywhere in the body, although they are most common in the gastrointestinal tract and lungs.

Rodney Pommier, MD, FACS, professor of surgery, division of surgical oncology, school of medicine, Oregon Health & Science University, discusses his presentation at the 2021 NANETS Virtual Symposium on a prospective study of carcinoid crisis with no perioperative octreotide.

The FDA also granted Priority Review designation for the toripalimab BLA and set a Prescription Drug User Fee Act action date for April 2022; however, the FDA is not currently planning to hold an advisory committee meeting to discuss the application.

Mei Ka Fong, PharmD, BCOP, said there are multiple treatment approaches for patients with NETs.

TNBC is the most aggressive and lethal form of the disease.

Ciltacabtagene autoleucel (cilta-cel) CAR T-cell therapy is currently being evaluated for the treatment of patients with relapsed and/or refractory multiple myeloma.

Study does not show clinically significant improvements in overall survival but does show benefits in secondary endpoints, which included rates of distant metastases, deaths due to prostate cancer, and PSA failure.

Study finds that 16.9% of stomach cancers, 11.9% of endometrial cancers, 11.0% of kidney cancers, 9.3% of colon cancers, 8.1% of esophageal cancers, 6.5% of female breast cancers, and 3.9% of urinary bladder cancers were associated with a low level of exercise.

Multiple strategies can be used to create an individualized approach to therapies and removing barriers for patients with cancer.

Pembrolizumab (Keytruda) can be used for multiple cancer types, including melanoma, non-small cell lung cancer, and head and neck squamous cell cancer.

Asciminib (Scemblix) approved for patients with Philadelphia chromosome–positive chronic myeloid leukemia (CML) in chronic phase who were previously administered 2 or more tyrosine kinase inhibitors.

The study was designed to evaluate elacestrant as a monotherapy compared to the standard of care for the treatment of estrogen receptor-positive/human epidermal growth factor receptor 2 advanced or metastatic breast cancer.

The analysis found that patients’ quality of life did not change significantly over time during treatment with immune checkpoint inhibitors.

Chemotherapy for colorectal cancer include 5-fluorouracil (5-FU), capecitabine (Xeloda), irinotecan (Camptosar), oxaliplatin (Eloxatin), and trifluridine and tipiracil (Lonsurf).

The phase 2 Elara trial for the follicular lymphoma treatment met its primary endpoints, Novartis says.

Sacituzumab govitecan-hziy (Trodelvy) is indicated for the treatment of patients with triple-negative breast cancer who have received 2 prior therapies at minimum for metastatic disease.

ARTISTRY-7 will analyze the anti-tumor activity and safety of the combination compared with chemotherapy for individuals with platinum-resistant ovarian cancer.

Investigators conclude that minimal residual disease cells, or those that survive the initial treatment, may carry some form of epigenetic and metabolic memory of the tumor.

After skin cancer, breast cancer is the most common cancer diagnosed in women in the United States.

The multi-institutional clinic trial also concluded that there was no negative impact to quality of life for these patients.

The investigators said that the trial data showed potentially clinically meaningful improvements in both progression-free survival and overall survival in pre-specified subgroups of patients based on the baseline inflammatory biomarker, hs-CRP, as well as other biomarker-defined subgroups.

The rate of distant metastasis at 10 years was 29% for individuals whose scores demonstrated more aggressive disease compared with 13% for those who showed lower risk.

Patients undergoing chemotherapy had lower COVID-19 antibody levels than patients undergoing targeted therapy following vaccination.

There is a survival advantage for those who were also treated with surgery, according to new study results.

Adam Olszewski, MD, associate professor of medicine in Alpert Medical School at Brown University, discusses his SOHO 2021 conference presentation on prognostication and treatment of Burkitt lymphoma in the modern era.

Officials with the FDA have approved Roche’s VENTANA PD-L1 (SP263) Assay as a diagnostic test to evaluate patients with non-small cell lung cancer (NSCLC) who are eligible to receive atezolizumab (Tecentriq, Genentech).